News ArticleAkums Drugs and Pharmaceuticals Releases Q2 and H1 2026 Unaudited Financial Results and Appoints Sanjay Kumar as Senior Management
Board approves financial statements for period ended September 30, 2026, and designates President-Operations as senior executive
Akums Drugs and Pharmaceuticals Limited announced its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, as reviewed by auditors Walker Chandiok & Co LLP. The company also designated Mr. Sanjay Kumar as Senior Management Personnel, President - Operations.
Akums Drugs and Pharmaceuticals Limited
Financial Results
Akums Drugs and Pharmaceuticals Limited disclosed its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, accompanied by limited review reports. Additionally, the company appointed Mr. Sanjay Kumar, President - Operations, as a Senior Management Personnel.
The Board of Directors met on November 2, 2026, to review and approve the unaudited financial results for the three and six-month periods ending September 30, 2026. The financial statements were prepared following Indian Accounting Standard 34 and were reviewed by Walker Chandiok & Co LLP, who reported no material misstatements.
No deviations or variations in the use of proceeds from the Initial Public Offer were reported, as all proceeds were fully utilized. The company also confirmed it is not required to submit deviation statements for upcoming quarters.
Mr. Sanjay Kumar was officially designated as Senior Management Personnel, reflecting his role as President - Operations within the company, as per the recommendation of the Nomination & Remuneration Committee.
Highlights
- Unaudited standalone and consolidated results approved for Q2 and H1 ending September 30, 2026.
- Limited review reports issued by Walker Chandiok & Co LLP with no qualifications.
- No deviations reported in utilization of IPO proceeds; 100% proceeds fully utilized.
- Mr. Sanjay Kumar appointed as Senior Management Personnel, President - Operations.
- Income tax demand of ₹600.92 million under appeal; no adjustment required in financial statements.
- Board meeting held on November 2, 2026, lasting from 2:33 PM to 4:23 PM IST.
Key Data Snapshot
What happened
- Akums Drugs and Pharmaceuticals approved its unaudited standalone and consolidated financial results for Q2 and H1 ended September 30, 2026.
- The financial results underwent limited review conducted by Walker Chandiok & Co LLP with no material misstatements identified.
- The company notified no deviations in usage of IPO proceeds as the entirety has been utilized.
- Mr. Sanjay Kumar was designated as Senior Management Personnel, strengthening the leadership team.
Key details
- Financial results prepared per Indian Accounting Standard 34 with compliance to SEBI Listing Regulations.
- Income tax demand totaling ₹600.92 million is under appeal; management does not expect adjustments.
- Review reports include figures for affiliated Akums Employee Benefit Trust and a limited liability partnership, with respective audits.
- The Board meeting occurred on November 2, 2026, from 2:33 PM to 4:23 PM IST.
- Official communication was filed with BSE and National Stock Exchange and publicly posted on the company's website.
Regulatory and governance context
- The financial results were disclosed according to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Statement of deviation or variation from the use of IPO proceeds submitted as per Regulation 32 with no deviations reported.
- Designation of senior management personnel follows nomination and remuneration committee recommendations and SEBI master circular guidelines.
Highlights
- Unaudited standalone and consolidated results approved for Q2 and H1 ending September 30, 2026.
- Limited review reports issued by Walker Chandiok & Co LLP with no qualifications.
- No deviations reported in utilization of IPO proceeds; 100% proceeds fully utilized.
- Mr. Sanjay Kumar appointed as Senior Management Personnel, President - Operations.
- Income tax demand of ₹600.92 million under appeal; no adjustment required in financial statements.
- Board meeting held on November 2, 2026, lasting from 2:33 PM to 4:23 PM IST.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- Regulation 30, 32, 33 of SEBI LODR
- SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026
More News on Financial Results
View allLatest corporate announcements and market updates in Financial Results.
Lloyds Engineering Posts 110% Revenue Growth and Rs. 4,591.67 Crore Order Book in H1 FY2027
Lloyds Engineering Works Limited declared its unaudited financial results for the quarter and half year ended September 30, 2026, reporting a consolidated revenue of Rs. 1,120.70 crore, an increase of approximately 110% over the previous equivalent period, alongside a substantial rise in its consolidated order book position to Rs. 4,591.67 crore as of October 1, 2026.
Read Full Story
National Aluminium Company Reports Q2 2026 Unaudited Financial Results and Declares Rs.4.50 Interim Dividend per Share for FY 2026-27
National Aluminium Company Limited announced its unaudited standalone and consolidated financial results for the second quarter and half year ended 30th September 2026. The board also approved an interim dividend of Rs.4.50 per share for the financial year 2026-27, payable to shareholders registered by 6th November 2026.
Read Full Story
Ventive Hospitality Announces Q2 and H1 FY2027 Unaudited Results and Rs. 200 Crore Loan Support for Subsidiary
Ventive Hospitality Limited released its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, and approved a Letter of Comfort to ICICI Bank for a Rs. 200 crore loan facility for its wholly owned subsidiary KBJ Hotel & Restaurants Private Limited.
Read Full Story
